ROQUEFORT THERAPEUTICS PLC Logo

ROQUEFORT THERAPEUTICS PLC

Developing first-in-class, pre-clinical medicines for hard-to-treat cancers.

ROQ | IL

Overview

Corporate Details

ISIN(s):
GB00BMDQ2T15
LEI:
254900P4SISIWOR9RH34
Country:
United Kingdom
Address:
85 Great Portland Street, W1W 7LT London
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Roquefort Therapeutics plc is a biotechnology company focused on developing a portfolio of first-in-class medicines for hard-to-treat cancers. Its pipeline consists of five novel, patent-protected, pre-clinical anti-cancer programs targeting malignancies resistant to existing therapies within the high-growth immuno-oncology market. The company employs a scalable and cost-effective distributed R&D model, combining its in-house, state-of-the-art laboratory capabilities with a network of academic research partnerships. Founded in 2020, Roquefort Therapeutics is led by an experienced team with a proven track record in drug development, regulatory processes, and biotech transactions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-16 08:00
Capital/Financing Update
Fundraise & Transaction Update
English 16.2 KB
2025-09-08 08:00
M&A Activity
Proposed Acquisition of Clinical Stage Company
English 26.7 KB
2025-07-07 08:00
Director's Dealing
Director/PDMR Shareholding
English 24.3 KB
2025-06-30 08:00
Director's Dealing
Director/PDMR Shareholding
English 24.4 KB
2025-06-27 08:00
M&A Activity
Lyramid SPA Extension
English 14.1 KB
2025-06-26 14:00
Declaration of Voting Results & Voting Rights Announcements
Results of AGM
English 25.0 KB
2025-06-02 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting
English 10.3 KB
2025-05-23 08:00
Capital/Financing Update
Extension of Convertible Loan Notes
English 11.9 KB
2025-05-20 08:50
Annual Report (ESEF)
2024 Annual Report
English 1.8 MB
2025-05-20 08:50
Annual Report
2024 Annual Report
English 3.9 MB
2025-03-14 08:00
Capital/Financing Update
Private Placing and Conversion of CLNs
English 14.5 KB
2025-03-10 08:30
Board/Management Information
Board Changes
English 14.4 KB
2025-03-10 08:00
M&A Activity
Proposed Sale of Oncogeni Ltd
English 13.5 KB
2025-03-04 08:00
Regulatory News Service
Update on Sale of Lyramid
English 15.0 KB
2025-02-04 11:58
Director's Dealing
Director/PDMR Shareholding
English 35.8 KB

Automate Your Workflow. Get a real-time feed of all ROQUEFORT THERAPEUTICS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ROQUEFORT THERAPEUTICS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ROQUEFORT THERAPEUTICS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Developing novel cancer immunotherapies, including peptide vaccines and iPS-NKT cell therapies.
Japan 4594
Brilliant Future AB Logo
A data-driven survey platform to measure and improve employee & customer experiences.
Sweden BRILL
b-style holdings,Inc. Logo
Offers flexible staffing for homemakers and specialized recruitment for skilled professionals.
Japan 302A
BTS Group Logo
Helps organizations execute strategy via experiential learning for leadership and sales teams.
Sweden BTS
B.U Technology Logo
Commercializes university research via IP management, licensing, and new venture creation.
South Korea 230980
Advancing high-grade copper and precious metal projects from discovery to production.
Canada N/A
Cantargia Logo
Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland CTX
Offers one-stop BPO, CRM, and staffing for admin, manufacturing, and logistics.
Japan 6070
Carna Biosciences, Inc. Logo
Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.
Japan 4572

Talk to a Data Expert

Have a question? We'll get back to you promptly.